Kairos Pharma to host KOL event Sept 18 for ENV105 Phase 2 interim efficacy data

Kairos Pharma, LTD.

Virtual KOL event on Sept 18, 2025, at 5 p.m. ET to discuss interim efficacy results from ENV105 Phase 2 trial in advanced prostate cancer.
ENV105 is a first-in-class CD105 antagonist; interim safety analysis (July 2025) showed well-tolerated with no dose-limiting toxicities or Grade 3/4 events.
Speakers include principal investigators Drs. Bhowmick, Swami, Lee, and Posadas.
ENV105 targets CD105-driven drug resistance in castration-resistant prostate cancer; trial combines ENV105 with apalutamide.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.